<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03034564</url>
  </required_header>
  <id_info>
    <org_study_id>16-159</org_study_id>
    <nct_id>NCT03034564</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cooper Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cooper Health System</source>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled trial comparing droxidopa to placebo&#xD;
      for fatigue in Parkinson's Disease. The primary outcome measure is change in the Parkinson's&#xD;
      Disease Fatigue Scale, a 16-item scale that measures the physical effects of fatigue as well&#xD;
      as the impact of fatigue on daily functioning and activities, including socialization.&#xD;
      Secondary outcomes are the PDQ-39, a 39-item self-report questionnaire assessing Parkinson's&#xD;
      disease-specific health related quality over the last month in 8 different dimensions of&#xD;
      function and well-being, and the Epworth Sleepiness Scale, a questionnaire querying 8&#xD;
      situations for which the subject will rate the likelihood of falling asleep. There will be a&#xD;
      screening visit (SC), baseline visit (BL), 2 clinic visits at 6 and 12 weeks (V01, V02), and&#xD;
      telephone contact at 4 weeks and 8 weeks (T1, T2). In-person visits will include review of&#xD;
      informed consent, concomitant medication review, adverse event review, pill counts, vital&#xD;
      signs (including supine blood pressure), and outcome measurements. Telephone visits will&#xD;
      include review of informed consent, concomitant medication review, and adverse event review.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2017</start_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parkinson's Disease Fatigue Scale</measure>
    <time_frame>Week 12</time_frame>
    <description>16-item scale that measures the physical effects of fatigue as well as the impact of fatigue on daily functioning and activities, including socialization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PDQ-39</measure>
    <time_frame>Week 12</time_frame>
    <description>a 39-item self-report questionnaire assessing Parkinson's disease-specific health related quality over the last month in 8 different dimensions of function and well-being</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale</measure>
    <time_frame>Week 12</time_frame>
    <description>a questionnaire querying 8 situations for which the subject will rate the likelihood of falling asleep</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Fatigue</condition>
  <condition>Parkinsonism</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active group started 100 mg TID, increased by 100 mg per interval (i.e. 100 TID) every 2 days till on 600 TID, or until intolerable dose is achieved at which time the next highest dose will be maintained (increments of 100 TID will be used).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosing regimen identical to active group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Northera</intervention_name>
    <arm_group_label>1</arm_group_label>
    <other_name>Droxidopa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Parkinson's Disease&#xD;
&#xD;
          -  Have normal kidney function (determined at screening visit by blood sample analysis),&#xD;
             and no active medical diagnoses associated with fatigue&#xD;
&#xD;
          -  No orthostatic symptoms (i.e. light headedness, blurred vision, and/or muscle&#xD;
             weakness)&#xD;
&#xD;
          -  No objective orthostasis (significant drop in blood pressure when standing)&#xD;
&#xD;
          -  No supine hypertension (high blood pressure while laying down) judged to be of&#xD;
             clinical significance by the investigator&#xD;
&#xD;
          -  Well-controlled depression&#xD;
&#xD;
          -  Stable dopaminergic medication regimen for 6 weeks prior to screening&#xD;
&#xD;
          -  No concurrent use of fludrocortisone, midodrine, or other medications that may raise&#xD;
             blood pressure&#xD;
&#xD;
          -  PD Fatigue Scale Score of 50 or above&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Atypical Parkinsonism (having symptoms that mimic PD without a PD&#xD;
             diagnosis)&#xD;
&#xD;
          -  Prior Intolerance of droxidopa&#xD;
&#xD;
          -  SNRI or TCA class (both antidepressant) medications (irrespective of indication)&#xD;
&#xD;
          -  Use of activating agents (amantadine, modafinil, methylphenidate and related&#xD;
             stimulants)&#xD;
&#xD;
          -  Significant cardiac disease history&#xD;
&#xD;
          -  Significant kidney disease history, or creatinine (a chemical found in the blood)&#xD;
             greater than 1.5 mg/dl at baseline&#xD;
&#xD;
          -  Poorly controlled depression&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Significant history of Gastro Intestinal disease that may interfere with absorption&#xD;
             (gastric bypass, inflammatory bowel disease)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew McGarry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cooper Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew March, BS</last_name>
    <phone>856-342-2460</phone>
    <email>march-andrew@cooperhealth.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cooper University Health System</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew March, BS</last_name>
      <phone>856-342-2460</phone>
      <email>march-andrew@cooperhealth.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew McGarry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amy Colcher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 25, 2017</study_first_submitted>
  <study_first_submitted_qc>January 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2017</study_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Droxidopa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

